Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
Profitability metrics exhibit a consistent downward trajectory from early 2022 through early 2026, characterized by a significant compression in margins and a reduction in returns on capital.
- Gross Profit Margin
- The gross profit margin remained the most stable of the analyzed ratios, although a gradual overall decline is evident. Starting at 60.77%, the margin reached a low of 58.39% in March 2024 before ending the period at 58.94%. The relative stability of this metric suggests that direct costs of sales have remained largely proportional to revenue.
- Operating and Net Profit Margins
- A pronounced contraction is observed in both operating and net profit margins. Operating profit margins peaked at 27.61% in December 2022 but declined steadily to 19.21% by March 2026. Net profit margins followed a similar pattern, reaching a high of 23.32% in March 2023 before falling to 14.89% by March 2026. The divergence between the stable gross margin and the declining operating margin indicates that increasing operating expenses have been the primary driver of profitability erosion.
- Return on Equity (ROE) and Return on Assets (ROA)
- Returns on invested capital show a significant erosion in efficiency. ROE declined from 13.93% in April 2022 to 6.97% by March 2026, representing a near-halving of the return to shareholders. Simultaneously, ROA decreased from 7.74% at the start of the period to 4.42% by the conclusion. The synchronized decline in both metrics reflects the broader compression of net profitability and a diminished effectiveness in utilizing assets to generate earnings.
Return on Sales
Return on Investment
Gross Profit Margin
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||
| Sales | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
Gross profit margin = 100
× (Gross profitQ1 2026
+ Gross profitQ4 2025
+ Gross profitQ3 2025
+ Gross profitQ2 2025)
÷ (SalesQ1 2026
+ SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
An analysis of the financial performance from April 2022 through March 2026 reveals a significant shift in the company's scale of operations and a subsequent adjustment in profitability margins. A notable contraction in both sales and gross profit occurred between December 2022 and March 2023, marking a transition from a higher revenue base to a lower, more stable operating level.
- Revenue and Profit Volume Trends
- Sales figures remained robust throughout 2022, peaking at 8,369 million USD in December 2022. However, a sharp decline was observed in the first quarter of 2023, with sales dropping to 5,949 million USD. Following this correction, revenue levels fluctuated between approximately 5,700 million USD and 6,800 million USD through March 2026. Gross profit followed a similar trajectory, decreasing from a peak of 4,939 million USD in late 2022 to a range of 3,400 million USD to 3,900 million USD in subsequent periods.
- Gross Profit Margin Trajectory
- The gross profit margin exhibited three distinct phases. From April 2022 to December 2022, margins remained highly stable and strong, consistently exceeding 60%. A downward trend emerged in 2023, with the margin sliding from 60.22% in March 2023 to a period low of 58.39% by March 2024. This indicates a period of increased cost of goods sold relative to revenue or a shift in the product mix toward lower-margin offerings.
- Margin Stabilization and Current Status
- Beginning in June 2024, the gross profit margin entered a phase of relative stabilization. For the remainder of the analyzed period, the margin fluctuated within a narrow band between 58.94% and 59.74%. Although the margin has not returned to the 60% threshold observed in 2022, the volatility has diminished, suggesting a new equilibrium in the cost structure and pricing strategy.
Operating Profit Margin
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Operating profit | |||||||||||||||||||||||
| Sales | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
Operating profit margin = 100
× (Operating profitQ1 2026
+ Operating profitQ4 2025
+ Operating profitQ3 2025
+ Operating profitQ2 2025)
÷ (SalesQ1 2026
+ SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
An analysis of the operating profit margin reveals a distinct cyclical pattern characterized by an initial peak, a prolonged period of contraction, and a subsequent phase of marginal stabilization. The profitability metrics indicate a significant shift in operational efficiency starting in the first quarter of 2023, coinciding with a notable reduction in overall sales volume.
- Peak Profitability Phase (2022)
- During the period from April 2022 to December 2022, the operating profit margin exhibited an upward trend, rising from 25.23% to a peak of 27.61%. This growth occurred alongside strong sales figures, which reached a high of 8,369 million USD in December 2022, suggesting high operational leverage and efficiency during this interval.
- Period of Margin Compression (2023 – 2024)
- A sustained downward trajectory in profitability is observed beginning in March 2023. The operating profit margin declined from 27.02% to 20.11% by September 2024. This contraction was mirrored by a substantial drop in quarterly sales, which fell from the 7,000–8,000 million USD range seen in 2022 to a range between 5,600 and 6,500 million USD throughout 2023 and 2024.
- Trough and Stabilization Phase (2025 – 2026)
- The operating profit margin reached its lowest point of 18.39% in June 2025. Following this trough, a gradual recovery is evident, with the margin incrementally increasing to 19.01% in September 2025, 19.09% in December 2025, and finally reaching 19.21% by March 2026. While these figures indicate a stabilization of costs relative to revenue, they remain significantly below the efficiency levels recorded in 2022.
Net Profit Margin
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||
| Sales | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
Net profit margin = 100
× (Net earningsQ1 2026
+ Net earningsQ4 2025
+ Net earningsQ3 2025
+ Net earningsQ2 2025)
÷ (SalesQ1 2026
+ SalesQ4 2025
+ SalesQ3 2025
+ SalesQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
A significant contraction in profitability is evident over the analyzed period. While the company maintained strong net profit margins exceeding 20% throughout 2022 and the first three quarters of 2023, a sustained downward trend followed, reaching a trough in mid-2025 before demonstrating signs of marginal stabilization.
- Peak Profitability Phase
- Between April 2022 and September 2023, net profit margins remained robust, fluctuating between a low of 20.61% and a peak of 23.32% in March 2023. During this window, net earnings frequently exceeded $1.5 billion per quarter, supported by sales volumes generally ranging between $5.6 billion and $8.3 billion.
- Margin Compression Period
- A definitive decline in profitability began in December 2023, where the net profit margin dropped below the 20% threshold to 19.94%. This downward trajectory continued consistently for eighteen months, culminating in a period low of 14.21% in June 2025. This decline occurred despite sales remaining relatively stable between $5.7 billion and $6.5 billion during the 2024 fiscal year, suggesting that the margin erosion was driven more by increasing costs or reduced pricing power than by a collapse in revenue.
- Earnings Volatility
- Net earnings exhibited substantial volatility, falling from a high of $2,232 million in December 2022 to a low of $555 million in June 2025. The disparity between the stability of sales and the sharp decline in net earnings underscores a significant reduction in operational efficiency or an increase in non-operating expenses during the 2024-2025 period.
- Recent Stabilization Trend
- Starting in September 2025, a gradual recovery in the net profit margin is observed. The margin climbed incrementally from 14.43% in September 2025 to 14.89% by March 2026. While this represents a stabilization, the current profitability levels remain substantially lower than the benchmarks established in 2022 and early 2023.
Return on Equity (ROE)
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||
| Total Danaher stockholders’ equity | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
ROE = 100
× (Net earningsQ1 2026
+ Net earningsQ4 2025
+ Net earningsQ3 2025
+ Net earningsQ2 2025)
÷ Total Danaher stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
A sustained downward trend in Return on Equity (ROE) is observed from April 2022 through March 2026. The metric peaked in late 2022 at 14.40% before entering a period of progressive decline, eventually stabilizing in the range of 6.5% to 7.0% during the 2025 and early 2026 periods.
- Net Earnings Performance
- The decline in ROE is primarily attributed to a reduction in net earnings. Profits reached a peak of 2,232 million US$ in December 2022 but experienced a general contraction throughout 2023 and 2024. A significant trough occurred in June 2025, where earnings fell to 555 million US$, coinciding with the lowest ROE of 6.52%.
- Equity Growth and Stability
- Total stockholders' equity exhibited a steady increase during the first half of the analyzed period, rising from 46,356 million US$ in April 2022 to a peak of 53,486 million US$ by December 2023. From 2024 onward, equity levels remained relatively stable, fluctuating between approximately 49,500 million US$ and 53,000 million US$. This indicates that the compression of ROE was driven by falling numerator values (earnings) rather than a substantial expansion of the capital base.
- Profitability Convergence
- Between December 2022 and December 2023, the ROE experienced its most rapid deceleration, falling from 14.39% to 8.91%. While a slight recovery in net earnings is noted toward the end of 2025 and early 2026, the ROE remains significantly lower than the 2022 benchmarks, settling at 6.97% as of March 2026.
Return on Assets (ROA)
| Mar 27, 2026 | Dec 31, 2025 | Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-27), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01).
1 Q1 2026 Calculation
ROA = 100
× (Net earningsQ1 2026
+ Net earningsQ4 2025
+ Net earningsQ3 2025
+ Net earningsQ2 2025)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analyzed period reveals a significant contraction in asset utilization efficiency. After reaching a peak in the fourth quarter of 2022, the Return on Assets (ROA) entered a sustained decline, transitioning from a high of 8.55% to a stabilized range between 4.18% and 4.42% by early 2026.
- Net Earnings Trajectory
- A substantial reduction in profitability is evident. Net earnings peaked at 2,232 million USD in December 2022 but experienced a notable downward shift throughout 2023 and 2024. A significant trough occurred in June 2025, where earnings fell to 555 million USD, before recovering to 1,029 million USD by March 2026.
- Asset Base Stability
- Total assets remained relatively stable compared to the volatility of earnings. Asset values fluctuated within a corridor of approximately 77.5 billion USD to 87.7 billion USD. This relative stability suggests that the decline in ROA was not driven by an aggressive expansion of the asset base, but rather by a diminished capacity of existing assets to generate net income.
- ROA Trend Analysis
- The return on assets exhibited a clear bifurcated trend. The initial phase, ending in December 2022, showed growth and efficiency. The subsequent phase, spanning 2023 through 2026, was characterized by a steady erosion of returns. The ratio dropped below 6% by the end of 2023 and continued to diminish, eventually stabilizing around the 4.3% mark in the final quarters of the period.